This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CNCE Concert Pharmaceuticals (CNCE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Concert Pharmaceuticals Stock (NASDAQ:CNCE) 30 days 90 days 365 days Advanced Chart Remove Ads Get CNCE alerts:Sign Up Key Stats Today's Range$8.37▼$8.3750-Day Range$8.33▼$8.4052-Week Range$2.66▼$8.55VolumeN/AAverage Volume2.97 million shsMarket Capitalization$401.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewConcert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.Read More… Remove Ads Receive CNCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CNCE Stock News HeadlinesMagnum Wrestling event in Ralston will benefit pediatric cancer organizationSeptember 27, 2024 | omaha.comStar-Studded Rock4EB! Concert Raises Over $1 Million for 'Butterfly' Skin Disease Epidermolysis BullosaSeptember 23, 2024 | nz.news.yahoo.comAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.April 4, 2025 | Paradigm Press (Ad)Man who sold fentanyl-laced pill liable for $5.8 million in death of young female customerSeptember 20, 2024 | msn.comJaney Godley cancels tour and stops work ‘for the foreseeable future’September 18, 2024 | msn.comJane's Addiction cancels tour in the wake of an onstage fightSeptember 16, 2024 | msn.comHair loss, nosebleeds, and a Taylor Swift concert: How I coped with chemoSeptember 15, 2024 | msn.comBreast cancer drug could help prolong survival for children with brain tumors, study findsSeptember 6, 2024 | msn.comSee More Headlines CNCE Stock Analysis - Frequently Asked Questions How were Concert Pharmaceuticals' earnings last quarter? Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) announced its earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.78) EPS for the quarter, topping analysts' consensus estimates of ($0.81) by $0.03. The biotechnology company earned $0.54 million during the quarter, compared to the consensus estimate of $0.25 million. What other stocks do shareholders of Concert Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Concert Pharmaceuticals investors own include Intel (INTC), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Global Blood Therapeutics (GBT), Micron Technology (MU), Pfizer (PFE) and NVIDIA (NVDA). Company Calendar Last Earnings11/09/2021Today4/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CNCE CIK1367920 Webwww.concertpharma.com Phone(781) 860-0045Fax302-636-5454Employees64Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-80,050,000.00 Net MarginsN/A Pretax Margin-300,735.69% Return on Equity-109.43% Return on Assets-76.65% Debt Debt-to-Equity RatioN/A Current Ratio9.03 Quick Ratio9.03 Sales & Book Value Annual Sales$32.58 million Price / Sales12.32 Cash FlowN/A Price / Cash FlowN/A Book Value$3.24 per share Price / Book2.58Miscellaneous Outstanding Shares47,940,000Free Float42,507,000Market Cap$401.26 million OptionableOptionable Beta0.52 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:CNCE) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredWall St. Icon: Looming Financial Tsunami Could Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event could hit the America...InvestorPlace | SponsoredControversial opinion: Volume isn't enough.Don’t be fooled by volume alone — it's just one piece of the trading puzzle. High demand doesn’t matter if sup...MillPub | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Concert Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Concert Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.